Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02150499 · ClinicalTrials.gov registry record · Phase 3
A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Terminated
- Registry status
- Phase 3
- Development phase
- 18
- Enrollment target
NCT02150499 is a Phase 3 study that was terminated before completion, run by Sumitomo Pharma America. The registered enrollment target is 18 participants.
The verdict
NCT02150499, a Phase 3 study, was terminated before completion, sponsored by Sumitomo Pharma America.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a study of levalbuterol tartrate HFA inhalation aerosol MDI in pediatric subjects birth to ≤ 48 months of age who go to the Emergency Department (ED) or their physician's office with an acute bronchospasm. Subjects presenting to the ED or physician's office with an acute bronchospasm must have a history of reactive airways disease, based on subjects' parent/guardian report.
Interventions
- DRUG placebo
- DRUG levalbuterol tartrate HFA inhalation aerosol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-07 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02150499
The ClinicalTrials.gov registry entry for NCT02150499 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02150499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02150499 about?
NCT02150499 is a clinical study titled "A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects". This is a study of levalbuterol tartrate HFA inhalation aerosol MDI in pediatric subjects birth to ≤ 48 months of age who go to the Emergency Department (ED) or their physician's office with an acute bronchospasm. Subjects presenting to the ED or physician's office with an acute bronchospasm must ha...
What is the current status of trial NCT02150499?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 18 participants. The study started on 2014-07. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02150499?
The interventions under investigation include: placebo (DRUG), levalbuterol tartrate HFA inhalation aerosol (DRUG).
Who is sponsoring clinical trial NCT02150499?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.